Colorectal Tumors
Conditions
Keywords
Fructose, D-Xylose, Primary Human Colorectal Tumors
Brief summary
This proposed study is designed to investigate the specific uptake of fructose by human colorectal tumors. In this study, subjects with colorectal cancer undergoing surgery will receive an oral sugar solution containing fructose or xylose prior to surgery. The tumor will then be resected, and a portion of the tissue will be used to measure the abundance of fructose and xylose. The study hypothesis is that the tumors will take up fructose sugar but not xylose sugar. A comparison of the sugar uptake between the tumor and normal tissues from the adjacent intestinal epithelium and smooth muscle and the liver will be conducted. This proposal will confirm that human colorectal cancer tumors can directly absorb dietary sugars, which has never been demonstrated.
Detailed description
This prospective pilot study is designed to investigate the uptake of dietary fructose and xylose by primary human colon tumors. In this study, the recruited patients with colorectal cancer will receive an oral sugar solution containing either Fructose sugar or Xylose sugar before surgery. The tumor will then be resected and a portion of the tumor, normal intestinal tissue, blood, urine, and liver will be used to quantify fructose and xylose. * Research question Can primary human tumors take up fructose or xylose? * A statement of the hypothesis The hypothesis is that fructose, but not xylose, can be directly absorbed and stored by primary human colon tumors. * Design Prospective, non-randomized, pilot, feasibility, single-center, open-label, phase 1, investigator-initiated study to evaluate the uptake of dietary fructose and xylose by primary human colon tumors with 12 subjects in 2 cohorts: Cohort 1: 6 subjects will consume a sugar solution containing fructose and Cohort 2: 6 subjects will consume a sugar solution containing xylose. Eligible subjects that are scheduled to undergo colorectal resection for cancer treatment will be invited to participate in the study in consecutive order from the practice of colorectal surgeons at the time of their preoperative clinic visit. First, Cohort 1 subjects will be enrolled followed by the Cohort 2 subjects. N=12 Subjects Cohort 1: Fructose sugar solution =6 Subjects Cohort 2: Xylose sugar solution=6 Subjects
Interventions
DIETARY_SUPPLEMENTCohort 1: HFCS (fructose) fed
Two to three hours before surgery. Subjects will prepare the sugar solutions (Fructose-containing solution: 250 mL of water containing 41.25 g of D-Fructose and 33.75 g of D-Glucose) by adding 250 ml water to the sugar powder provided by the study team and drink it between two and three hours before surgery. Samples collected before surgery: * Blood sample of 5 ml * Urine Samples 5 ml Day of Surgery The anesthesia and surgical procedure will undergo as per regular care. Samples collection at the time the surgical specimen is removed * Blood sample of 5 ml blood will be obtained from the IV line * Tissue samples * 2 Tumor tissue samples 5mmx5mmx5mm, * 2 Intestinal /colon tissue samples 5mmx5mmx5mm * 2 tissue samples from mesentery tissue 5mmx5mmx5mm * Optional Liver Biopsy - a 3-5 mm liver tissue will be obtained for research. * Urine Samples 5 ml
DIETARY_SUPPLEMENTCohort 2: D-Xylose (xylose-fed)
Two to three hours before surgery. Subjects will prepare the sugar solutions (Xylose-containing solution: 250 mL of water containing 41.25 g of D-Xylose and 33.75g of D-Glucose) by adding 250 ml water to the sugar powder provided by the study team and drink it between two and three hours before surgery. Samples collected before surgery: * Blood sample of 5 ml * Urine Samples 5 ml Day of Surgery The anesthesia and surgical procedure will undergo as per regular care. Samples collection at the time the surgical specimen is removed * Blood sample of 5 ml blood will be obtained from the IV line * Tissue samples * 2 Tumor tissue samples 5mmx5mmx5mm, * 2 Intestinal /colon tissue samples 5mmx5mmx5mm * 2 tissue samples from mesentery tissue 5mmx5mmx5mm * Optional Liver Biopsy - a 3-5 mm liver tissue will be obtained for research. * Urine Samples 5 ml
Sponsors
Weill Medical College of Cornell University
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
BASIC_SCIENCE
Masking
NONE
Intervention model description
Prospective, pilot, feasibility, single-center, non-randomized, open-label, phase 1, investigator-initiated study to evaluate the specific uptake of fructose by human colorectal tumors with 12 subjects in 2 cohorts: Cohort 1: fructose-fed with 6 subjects Cohort 2: xylose-fed with 6 subjects. Eligible subjects scheduled to undergo colorectal resection for cancer treatment will be invited to participate in the study in consecutive order from the practice of colorectal surgeons at the time of their preoperative clinic visit. First, Cohort 1 subjects will be enrolled followed by the Cohort 2 subjects.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Subjects of 18 years of age or older, male, and female * Subjects with a diagnosis of invasive non-hereditary colonic adenocarcinoma who will be undergoing standard of care (SOC) laparoscopic, robot-assisted, or open surgical resection * The subject provides informed consent
Exclusion criteria
* Subjects with a history of uncontrolled diabetes mellitus (A1C \>7.0) Type I and Type 2, will be excluded to avoid potential confounders associated with the consumption of a large bolus of sugar (e.g., hyperglycemia and hyperinsulinemia) * Inflammatory Bowel Disease (Ulcerative Colitis or Crohn's Disease) * Patients on steroid medications * Patients with current infectious disease * Subjects who do not speak English
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The abundance of fructose in tumor extracts | Morning after the consumption of oral sugar solutions(during surgery at the time of specimen removal) | The abundance of fructose in tumor extracts assessed by mass spectrometry in the morning after the consumption of oral sugar solutions. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Abundance of Fructose and [13C]-Fructose in the urine | Morning after the consumption of oral sugar solutions(during surgery at the time of specimen removal) | The abundance of Fructose and \[13C\]-Fructose in the urine in the morning after the consumption of oral sugar solutions assessed by mass spectrometry. |
| Abundance of Fructose and [13C]-Fructose in the liver | Morning after the consumption of oral sugar solutions(during surgery at the time of specimen removal) | The abundance of Fructose and \[13C\]-Fructose in the liver tissue in the morning after the consumption of oral sugar solutions assessed by mass spectrometry. |
| Abundance of Fructose and [13C]-Fructose in the intestine | Morning after the consumption of oral sugar solutions(during surgery at the time of specimen removal) | The abundance of Fructose and \[13C\]-Fructose in the intestine tissue in the morning after the consumption of oral sugar solutions assessed by mass spectrometry. |
| Abundance of Fructose and [13C]-Fructose in the mesentery tissues | Morning after the consumption of oral sugar solutions(during surgery at the time of specimen removal) | The abundance of Fructose and \[13C\]-Fructose in the mesentery tissue in the morning after the consumption of oral sugar solutions assessed by mass spectrometry. |
| The abundance of Xylose and [13C]-Xylose in the blood | Morning after the consumption of oral sugar solutions(during surgery at the time of specimen removal) | The abundance of Xylose and \[13C\]-Xylose in the blood in the morning after the consumption of oral sugar solutions assessed by mass spectrometry. |
| The abundance of Fructose and [13C]-Fructose in the blood | Morning after the consumption of oral sugar solutions(during surgery at the time of specimen removal) | The abundance of Fructose and \[13C\]-Fructose in the blood in the morning after the consumption of oral sugar solutions assessed by mass spectrometry. |
| The abundance of Xylose and [13C]-Xylose in the liver | Morning after the consumption of oral sugar solutions(during surgery at the time of specimen removal) | The abundance of Xylose and \[13C\]-Xylose in the liver tissue in the morning after the consumption of oral sugar solutions assessed by mass spectrometry. |
| The abundance of Xylose and [13C]-Xylose in the intestinal tissue | Morning after the consumption of oral sugar solutions(during surgery at the time of specimen removal) | The abundance of Xylose and \[13C\]-Xylose in the intestinal tissue in the morning after the consumption of oral sugar solutions assessed by mass spectrometry. |
| The abundance of Xylose and [13C]-Xylose in the mesentery tissues | Morning after the consumption of oral sugar solutions(during surgery at the time of specimen removal) | The abundance of Xylose and \[13C\]-Xylose in the mesentery tissues in the morning after the consumption of oral sugar solutions assessed by mass spectrometry. |
| The abundance of Xylose and [13C]-Xylose in the in the tumor | Morning after the consumption of oral sugar solutions(during surgery at the time of specimen removal) | The abundance of Xylose and \[13C\]-Xylose in the tumor in the morning after the consumption of oral sugar solutions assessed by mass spectrometry. |
| The abundance of Xylose and [13C]-Xylose in the urine | Morning after the consumption of oral sugar solutions(during surgery at the time of specimen removal) | The abundance of Xylose and \[13C\]-Xylose in the urine in the morning after the consumption of oral sugar solutions assessed by mass spectrometry. |
Countries
United States
Outcome results
None listed